Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Los Bonos 1, 2 y 3 se encuentran actualmente cerrados. En las próximas semanas se proporcionará más información acerca de su apertura de cara a 2025.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
137
resultados
Última actualización
21/11/2024 [06:58:00]
Resultados 25 a 50 de 137
Resumen de: US2024366873A1
A model-based control scheme consisting of either a proportional-integral-derivative (IMC-PID) controller or a model predictive controller (MPC), with an insulin feedback (IFB) scheme personalized based on a priori subject characteristics and comprising a lower order control-relevant model to obtain PID or MPC controller for artificial pancreas (AP) applications.
Resumen de: WO2023122930A1
Disclosed is a highly integrated drug infusion device, comprising: a drug reservoir 112, used for accommodating the drug to be infused, provided with a piston and a screw; a driving wheel 114, connected with the screw, driving the screw to push the piston forward by rotation; a power supply 113, used to supply power to the infusion device; and a case, including an upper case 111a and a lower case 111b, for accommodating the drug reservoir 112, the drive wheel 114 and the power supply 113; wherein a three dimensional circuit 136 is provided on the case, and the three dimensional circuit 136 is electrically connected to the power supply 113 to supply power to the infusion device. The three dimensional circuit 136 is arranged on the case and does not occupy the internal space of the infusion device, which can make the internal arrangement of the infusion device more compact and further reduce the volume of the infusion device.
Resumen de: EP4458256A2
Electrochemical impedance spectroscopy (EIS) may be used in conjunction with continuous glucose monitoring (CGM) to enable identification of valid and reliable sensor data, as well implementation of Smart Calibration algorithms.
Resumen de: WO2023122929A1
A drug infusion device with integrated power supply comprises a drug reservoir, used for accommodating the drug to be infused, provided with a piston and a screw; a driving wheel, connected with the screw, driving the screw to push the pistion forward by rotation; a power supply, used to supply power to the infusion device, including a power supply shell, a power supply cell, electrolyte and a cover plate; and a case, including an upper case and a lower case, for accommodating the drug reservoir, the drive wheel and the power supply; the power supply shell is integrated with the lower and/or the cover plate is integrated with the upper case.
Resumen de: EP4406568A2
A fluid delivery device comprising a fluid reservoir; a transcutaneous access tool fluidly coupled to the fluid reservoir, the transcutaneous access tool including a needle or a trocar; and a transcutaneous access tool insertion mechanism for deploying the transcutaneous access tool, wherein the insertion mechanism is configured to insert and retract the needle/trocar in a single, uninterrupted motion. In certain embodiments, the fluid delivery device may comprise an infusion device comprising a fluid reservoir for containing a therapeutic fluid; and a transcutaneous access tool fluidly coupled to the fluid reservoir for delivering the therapeutic fluid subcutaneously and for introducing a monitoring test strip subcutaneously, and methods of use thereof.
Resumen de: WO2024226181A1
Provided herein are compact sensor continuously and wirelessly senses blood constituents including a mm-wave newly designed sensor validates its ability to correlate received base-band power levels variations, rather than S-parameters, with the variations in blood glucose levels of serum FBS and in that of the jugular veins and carotid arteries for animals and humans.
Resumen de: WO2024222121A1
The present application relates to a method and apparatus for analyzing a blood glucose concentration, a device, a storage medium, and a computer program product. The method comprises: acquiring intensity sets corresponding to a plurality of photoplethysmography pulse wave sets for a target object in a target time period, the intensity set comprising an average alternating-current intensity and an average direct-current intensity; performing curve fitting on the plurality of intensity sets to obtain a fitting coefficient and a fitting bias; comparing the fitting bias with a bias range corresponding to the target object, and when it is determined that the fitting bias is not within the bias range, adjusting the fitting bias to obtain an adjusted fitting bias; and performing, on the basis of the adjusted fitting bias, curve fitting on the plurality of intensity sets to obtain an adjusted fitting coefficient, and taking the adjusted fitting coefficient as the blood glucose concentration of the target object in the target time period. By adopting the method, the accuracy of blood glucose concentration analysis can be improved.
Resumen de: WO2024221034A1
Methods and systems for monitoring the value of blood glucose of a subject are described, the method including the steps of: continuously obtaining ECG parameters of the subject including heart rate, heart rate variability, QT interval and Tp/Rp ratio; inputting the obtained ECG parameters into a learning algorithm which processes the parameters; and outputting a continuously updated output value which is representative of the value of blood glucose of the subject.
Resumen de: AU2024227316A1
Systems and methods are provided relating to open loop decision-making for management of diabetes. People with diabetes face many problems in controlling their glucose because of the complex interactions between food, insulin, exercise, stress, activity, and other physiological and environmental conditions. Established principles of management of glucose sometimes are not adequate because there is a significant amount of variability in how different conditions impact different individuals and what actions might be effective for them. Accordingly, systems and methods according to present principles minimize the impact of the vagaries of diabetes on individuals, i.e., by looking for patterns and tendencies of an individual and customizing the management to that individual. Consequently, the same reduces the uncertainty that diabetes typically is associated with and improves quality of life.
Resumen de: AU2024227267A1
Flexible analyte sensors are provided. Flexible analyte sensors may be flexible continuous analyte sensors that facilitate continuous monitoring of an analyte such as blood glucose. The flexible analyte sensor may have a relatively flexible conductive or non-conductive core, may be formed from a plurality of substantially planar layers, or may be configured to transform from a freestanding sensor ex vivo to a non-freestanding sensor in vivo.
Resumen de: US2024358285A1
Provided is a continuous blood glucose measurement body attachment unit, which is manufactured in an assembled state in an applicator to minimize separate additional operations, such that the body attachment unit can be attached to the body with only a simple operation of the applicator and, particularly, the body attachment unit has a wireless communication chip to be capable of communicating with an external terminal, thereby enabling simple and convenient usage without an additional operation in which a separate transmitter must be connected and enabling maintenance to be more easily performed, and after the body attachment unit is attached to the body, an operation starts by the control of a user, such that an operation start time point can be adjusted to an appropriate time point according to the needs of the user, and an operation can start in a stabilized state, such that blood glucose can be accurately measured.
Resumen de: US2024358283A1
Systems and methods are disclosed for non-invasively measuring blood glucose levels in a biological sample based on spectral data. This includes at least one light source configured to strike a target area of a sample, at least one light detector positioned to receive light from the at least one light source and to generate an output signal, having a time dependent current, which is indicative of the power of light detected, a processor configured to receive the output signal from the at least one light detector based on the received output signal, calculate the attenuance attributable to blood in a sample present in the target area with a ratio factor, eliminate effect of uncertainty caused by temperature dependent detector response of the at least one light detector, and then determine a blood glucose level associated with a sample present in the target area based on the calculated attenuance with the processor.
Resumen de: US2024358294A1
Embodiments of the invention provide optimized polymeric surfaces adapted for use with implantable medical devices as well as methods for making and using such polymeric surfaces. These polymer surfaces have a constellation of features that function to inhibit or avoid an inflammatory immune response generated by implantable medical devices. Typical embodiments of the invention include an implantable glucose sensor used in the management of diabetes having a polymer surface with the disclosed constellation of features.
Resumen de: US2024358286A1
Provided is a continuous blood glucose measurement body attachment unit, which is manufactured in an assembled state in an applicator to minimize separate additional operations, such that the body attachment unit can be attached to the body with only a simple operation of the applicator and, particularly, the body attachment unit has a wireless communication chip to be capable of communicating with an external terminal, thereby enabling simple and convenient usage without an additional operation in which a separate transmitter must be connected and enabling maintenance to be more easily performed, and after the body attachment unit is attached to the body, an operation starts by the control of a user, such that an operation start time point can be adjusted to an appropriate time point according to the needs of the user, and an operation can start in a stabilized state, such that blood glucose can be accurately measured.
Resumen de: US2024358320A1
Disclosed are a diabetes sensor, a method for manufacturing the diabetes sensor, and a closed-loop control system. The diabetes sensor includes a substrate, a microneedle array arranged on one side of the substrate, and a plurality of electrodes covering the microneedle array and the substrate, wherein the microneedle array includes a plurality of microneedles; and the plurality of electrodes includes an electrochemical sensor and a reverse iontophoresis device; the electrochemical sensor being configured to detect glucose molecules in interstitial fluid and generate an electrical signal; and the reverse iontophoresis device being configured to generate a reverse iontophoresis effect to attract glucose molecules in a deep skin layer to an upper part of dermis where needle tips of the microneedles are located.
Resumen de: US2024358315A1
The subject matter of the present disclosure generally relates to techniques for neuromodulation that include applying energy (e.g., ultrasound energy) into the tissue to cause a change in a glucose transporter pathway molecule and/or an incretin pathway molecule. In one embodiment, the neuromodulation is performed as a treatment of a metabolic disorder.
Resumen de: US2024358282A1
A device includes a glucose monitor comprising at least one sensor electrode configured to sense signals indicative of interstitial glucose level of a patient. The device also includes a memory and one or more processors implemented in circuitry and in communication with the memory. The one or more processors are configured to cause delivery of a cleaning electrical current to the at least one sensor electrode. The cleaning electrical current is one or more electrochemical cleaning pulses configured to at least partially remove, in vivo and from the sensor electrode, excipients associated with the delivery of a fluid that includes insulin.
Resumen de: US2024358919A1
Systems comprising: an analyte sensor for providing an analyte signal representative of an analyte level; a controller in data communication with the analyte sensor and programmed to provide a recommended medication dose based on the analyte level and a medication type, the controller comprising a user interface for inputting the medication type; and a model-based safety mechanism integrated with the controller for evaluating the recommended medication dose. Wherein the model-based safety mechanism overrides the recommended medication dose and provides a safety medication dose when the model-based safety mechanism detects a risk of insulin deprivation.
Resumen de: US2024358920A1
Techniques disclosed herein relate to configurable target glucose values. In some embodiments, the techniques may involve modifying a glucose setpoint from a first target value to a second target value, wherein the second target value is lower than the first target value. The techniques may further involve regulating a glucose level of a patient to the modified glucose setpoint by controlling insulin delivery. The techniques may further involve after a time period has elapsed, reverting the glucose setpoint to the first target value.
Resumen de: US2024360230A1
The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-4 receptor (hIL-4R). The formulations may contain, in addition to an anti-hIL-4R antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
Resumen de: US2024362883A1
Modulation-encoded light, using different spectral bin coded light components, can illuminate a stationary or moving (relative) target object or scene. Response signal processing can use information about the respective different time-varying modulation functions, to decode to recover information about a respective response parameter affected by the target object or scene. Electrical or optical modulation encoding can be used. LED-based spectroscopic analysis of a composition of a target (e.g., SpO2, glucose, etc.) can be performed; such can optionally include decoding of encoded optical modulation functions. Baffles or apertures or optics can be used, such as to constrain light provided by particular LEDs. Coded light illumination can be used with a focal plane array light imager receiving response light for inspecting a moving semiconductor or other target. Encoding can use orthogonal functions, such as an RGB illumination sequence, or a sequence of combinations of spectrally contiguous or non-contiguous colors.
Resumen de: EP4454555A1
A device includes a glucose monitor comprising at least one sensor electrode configured to sense signals indicative of interstitial glucose level of a patient. The device also includes a memory and one or more processors implemented in circuitry and in communication with the memory. The one or more processors are configured to cause delivery of a cleaning electrical current to the at least one sensor electrode. The cleaning electrical current is one or more electrochemical cleaning pulses configured to at least partially remove, in vivo and from the sensor electrode, excipients associated with the delivery of a fluid that includes insulin.
Resumen de: EP4455655A1
An analyte sensor includes a microcontroller, a base layer, a conductive layer disposed on the base layer where the conductive layer includes a working electrode configured to provide a current signal in presence of glucose, an interference rejection membrane ("IRM") layer disposed on the working electrode where the IRM layer is negatively charged, and an enzyme layer disposed on the IRM layer where the enzyme layer includes an enzyme selected to generate a detectable electrical signal upon exposure to the glucose. The microcontroller is configured to process an electrochemical impedance spectroscopy (EIS) parameter to determine a state of the IRM layer.
Resumen de: NL2034650B1
The invention relates to an infusion element for infusing a substance into a body of a person, comprising: a housing that is suitable for being attached to the skin of said person, — an infusion means for infusing the substance into the body of said person, said infusion means being arranged on and/or protruding from the first surface of the housing; — at least one sensor for sensing a characteristic of the person, said sensor being arranged on and/or protruding from the first surface of the housing; wherein in use of the infusion element the infusion means is arranged for infusing said substance at a first depth and said sensor is arranged for sensing the characteristic at a second, different depth. The invention also relates to a system for regulating the concentration of glucose in the blood of a person comprising such an infusion element.
Nº publicación: HUE067393T2 28/10/2024
Solicitante:
UNIV DE SEVILLA [ES]
Universidad de Sevilla
Resumen de: MX2021008767A
The invention relates to a device (1) comprising a measuring unit (2) with a measuring module (4) for measuring the glucose level, a first computer module (5) for processing data from a first part of the process for measuring the glucose level, a first communications module (6), a first data storage module (7) and a pushbutton (8). The device also comprises a personal monitoring unit (3) with second and third communication modules (17, 20), a second computer module (18) for processing data from a second part of the process for measuring the glucose level, an interface module (19) and a second data storage module (22). Also described is a method for non-invasive blood glucose level estimation.
BOPI
Sede Electrónica
